Topics
Glioblastoma | Prognosis | Extent of resection
Home > Publications > Topics > Glioblastoma > Prognosis > Extent of resection
Gerritsen JKW, Young JS, Chang SM, Krieg SM, Jungk C, van den Bent
MJ, Satoer DD, Ille S, Schucht P, Nahed BV, Broekman MLD, Berger
M, De Vleeschouwer S, Vincent AJPE.
SUPRAMAX-study:
supramaximal resection versus maximal resection for glioblastoma
patients: study protocol for an international multicentre
prospective cohort study (ENCRAM 2201).
BMJ
Open. 2024 Apr 29;14(4):e082274. doi:
10.1136/bmjopen-2023-082274. PMID:
38684246. Interventional study protocol. ˍ
Dono A, Zhu P, Takayasu T, Arevalo O, Riascos R, Tandon N,
Ballester LY, Esquenazi Y.
Extent of
Resection Thresholds in Molecular Subgroups of Newly Diagnosed
Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Neurosurgery.
2024 Apr 30. doi:
10.1227/neu.0000000000002964. PMID:
38687046. Observational study˰
ˍ
Zeyen T, Böhm L, Paech D,
Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider
M, Potthoff AL,
Schneider-Rothhaar JL, Steinbach JP, Hau P, Kowalski T, Seidel
C, Krex D, Grauer O,
Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer
W, Hattingen E, Glas M,
Gkika E, Vatter H, Radbruch A, Herrlinger U, Weller J,
Schaub C.
Quantitative
assessment of residual tumor is a strong and independent
predictor
of survival in methylated glioblastoma following radiochemotherapy
with
CCNU/TMZ.
Neuro
Oncol. 2024 Oct
1:noae205. doi:
10.1093/neuonc/noae205.
PMID:
39351820. Observational study˰
ˍ